Top Page
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
(Sydney:IMR)
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (IMR) vs. iShares MSCI Australia ETF (EWA)
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Business Overview & Revenue Model
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 302.50K | 959.42K | 615.57K | 816.01K | 696.27K |
| Gross Profit | -2.10M | -924.12K | -1.12M | -1.53M | -1.90M |
| EBITDA | -22.56M | -15.55M | -21.87M | -16.47M | -19.57M |
| Net Income | -26.20M | -29.69M | -22.63M | -17.53M | -20.56M |
Balance Sheet | |||||
| Total Assets | 45.79M | 21.62M | 8.31M | 13.70M | 26.86M |
| Cash, Cash Equivalents and Short-Term Investments | 40.81M | 15.71M | 831.52K | 5.69M | 18.52M |
| Total Debt | 26.62M | 21.35M | 10.42M | 4.45M | 1.74M |
| Total Liabilities | 34.26M | 29.00M | 17.06M | 6.19M | 4.46M |
| Stockholders Equity | 11.53M | -7.38M | -12.83M | 7.51M | 22.40M |
Cash Flow | |||||
| Free Cash Flow | -20.20M | -15.65M | -13.06M | -17.06M | -18.11M |
| Operating Cash Flow | -19.75M | -15.57M | -12.98M | -16.82M | -17.49M |
| Investing Cash Flow | -22.47M | -74.98K | -82.78K | -238.86K | -695.30K |
| Financing Cash Flow | 44.55M | 30.33M | 8.21M | 3.94M | 11.59M |
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Technical Analysis
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$651.52M | -12.03 | -432.03% | ― | -8.99% | -18.16% | |
46 Neutral | AU$34.66M | -1.41 | -74.00% | ― | 23.31% | -17.35% | |
45 Neutral | AU$44.55M | -9.32 | -513.22% | ― | -34.06% | 75.47% | |
44 Neutral | AU$97.09M | -6.27 | -31.98% | ― | 34.20% | -23.90% | |
44 Neutral | AU$159.85M | -10.00 | -70.55% | ― | ― | -257.32% | |
41 Neutral | AU$48.65M | -2.66 | -128.19% | ― | -14.25% | -22.83% |
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Corporate Events
Imricor Medical Systems has released its FY 2025 investor presentation, providing general background information on its operations, financial reporting framework and regulatory context for its ASX-listed CHESS Depositary Interests. The company emphasises that the material is a high-level overview, may draw on unverified public sources and should not be relied upon as investment advice without independent professional guidance.
The release underscores extensive disclaimers regarding the accuracy and completeness of the information, highlights the use of U.S. GAAP and Regulation S safe harbour provisions for its securities, and clarifies that the document is not an offer to sell or solicit securities. It also cautions investors about risks and uncertainties associated with forward-looking information and notes restrictions on distributing the presentation outside Australia, signalling a strongly compliance-focused communication to the market.
The most recent analyst rating on (AU:IMR) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.
Imricor reported that FY2025 marked a pivotal year as it advanced its MRI-guided cardiac ablation platform with multiple second-generation products securing CE Mark approvals under the EU MDR and key components, including the Vision-MR Diagnostic Catheter and NorthStar, obtaining U.S. FDA clearance early in 2026. The company also launched landmark clinical initiatives such as the first-in-human ischemic VT ablation under real-time MRI guidance, expanded its VISABL trials across additional U.S. sites, and completed human factors studies involving physicians from nearly 20 hospitals.
Commercially, Imricor finished building and training its European sales team, growing its European customer pipeline from seven to 40 sites, while progressing Middle East expansion with two iCMR labs under construction in Saudi Arabia and an accredited summit in Riyadh. Financially, FY2025 revenue was modest at US$292,000 due to customers prioritising clinical trial enrolment, but the company ended the year with approximately US$40.8 million in cash and marketable securities and around US$19 million in operating cash outflows, underpinning its push to scale adoption of its MRI-native technology.
The most recent analyst rating on (AU:IMR) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.
Imricor Medical Systems reported a sharp decline in 2025 revenue to $292,309 from $959,424 a year earlier, driven by lower product sales as European customers shifted from commercial procedures to participation in the non‑revenue‑generating VISABL‑AFL clinical trial. Despite the revenue fall, the company’s GAAP net loss narrowed to $25.3 million, though an adjusted net loss of $21.0 million was 33% higher than the prior year, reflecting heavier operating spending.
Management significantly increased investment in sales, marketing, and research and development, expanding its European field team for the rollout of the NorthStar Mapping System and second‑generation consumables and beginning to build a U.S. commercial organisation ahead of regulatory approvals. Progress on clinical and regulatory fronts culminated in U.S. market clearance in January 2026 for the NorthStar Mapping System and Vision‑MR Diagnostic Catheter, while a strengthened liquidity position of about $40.8 million, boosted by a March 2025 capital raise, provides funding runway as the company pushes toward broader commercialisation and market penetration.
The most recent analyst rating on (AU:IMR) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.
Imricor Medical Systems has submitted its Advantage-MR electrophysiology (EP) Recorder/Stimulator system to the U.S. Food and Drug Administration for market clearance under the 510(k) pathway, a key step toward entering the U.S. market. The MR-conditional system acquires, processes and records intracardiac and surface ECG signals during EP studies and ablations, interfaces with MRI platforms from Siemens and Philips (and in future GE) to track Imricor’s MRI-compatible catheters via NorthStar, and integrates a programmable cardiac stimulator. By effectively acting as the connectivity “glue” that links catheters, MRI scanners, ablation generators, ECG systems and NorthStar into a unified interventional cardiac MRI lab solution, the Advantage-MR platform strengthens Imricor’s position in MRI-guided electrophysiology and could materially enhance its competitive standing and adoption prospects once cleared.
The most recent analyst rating on (AU:IMR) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.
Imricor Medical Systems has added Oklahoma Heart Institute as the fourth U.S. hospital site in its VISABL-AFL clinical trial, which is designed to support U.S. FDA approval of the company’s MRI-guided cardiac ablation products. Oklahoma Heart Institute’s cardiology-owned MRI infrastructure is expected to simplify implementation of interventional cardiac MRI procedures and, alongside existing U.S. and European trial centres, accelerate patient recruitment, shorten the approval timeline, and enable European sites to return sooner to revenue-generating clinical activity, potentially strengthening Imricor’s position in the evolving market for MRI-guided electrophysiology.
The most recent analyst rating on (AU:IMR) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.
Imricor Medical Systems has secured U.S. FDA 510(k) clearance for its NorthStar Mapping System, the first and only MRI-native 3D mapping and guidance platform to receive such approval, marking its first capital equipment and software-centric product cleared in the U.S. market. The clearance allows commercial launch of NorthStar in the world’s largest electrophysiology market and positions the system as the foundational software hub for interventional cardiac MRI labs, underpinning Imricor’s full MRI-guided electrophysiology platform and opening a new, AI-enabled software era for the company with substantial implications for future product expansion and market growth.
The most recent analyst rating on (AU:IMR) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.
Imricor Medical Systems reported its fourth-quarter 2025 activities, highlighting a series of clinical and technological milestones that advance real-time MRI-guided cardiac ablation toward broader global adoption. The company announced the world’s first ischemic ventricular tachycardia ablation and the first preclinical pulsed field ablation in the ventricle under real-time MRI guidance, expansion of its VISABL-AFL and VISABL-VT clinical trial programs with new U.S. and European hospital sites, and completed integration of its NorthStar system with Philips scanners, paving the way for site conversions in Europe and the Middle East while continuing integration work with General Electric ahead of a U.S. launch. Commercial momentum included a strengthened board with a former Johnson & Johnson MedTech executive, growing pipeline exceeding 40 sites, new iCMR lab construction and strong physician interest in Saudi Arabia, and heightened public visibility via television coverage. Financially, Imricor recorded operating cash outflows of US$5.2 million and minimal customer receipts in the quarter, reflecting the temporary revenue impact of enrolling hospitals in non-revenue-generating clinical trials, while ending 2025 with US$19.5 million in cash and US$21.3 million in short-term investments, positioning the company to fund its regulatory, clinical, and commercial execution as it seeks to solidify its role in redefining complex arrhythmia treatment without reliance on x-ray.
The most recent analyst rating on (AU:IMR) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.
Imricor Medical Systems has secured Institutional Review Board approval for Virginia Commonwealth University Health to join its VISABL-AFL clinical trial, making VCU Health the third U.S. site participating in the study supporting U.S. FDA approval of Imricor’s cardiac ablation products. With budgeting, installation and training expected to conclude in February and procedures slated to begin in March under Principal Investigator Dr Ajay Pillai, the addition of a large, nationally ranked academic health system underscores growing clinical interest in Imricor’s MRI‑guided NorthStar mapping system and Vision-MR mapping and ablation catheters, and marks a further step in advancing its U.S. regulatory and commercial positioning in cardiac ablation.
The most recent analyst rating on (AU:IMR) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.
Imricor Medical Systems Inc., an ASX-listed medical technology company focused on cardiac-related products, maintains its issued capital structure through various classes of securities, including options listed under the code IMRAJ. The company has notified the market that 52,500 IMRAJ options, which were subject to various exercise prices and expiry dates, have lapsed effective 1 January 2026 because the conditions for exercising these rights were not met or had become incapable of being satisfied, resulting in a modest reduction in potential future dilution for existing shareholders and a slight simplification of the company’s capital structure.
The most recent analyst rating on (AU:IMR) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.
Imricor Medical Systems has notified the market of the issue of 155,000 unquoted options under its employee incentive scheme, with various exercise prices and expiry dates, effective 1 January 2026. The new options, which will not be quoted on the ASX, form part of the company’s broader strategy to align staff incentives with shareholder interests and support retention and motivation of key employees as it advances its medical technology portfolio.
The most recent analyst rating on (AU:IMR) stock is a Buy with a A$2.22 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.
Imricor Medical Systems has received its first-ever clearance from the US Food and Drug Administration for the Vision-MR Diagnostic Catheter, an MRI-guided electrophysiology device that forms a key element of its MRI-compatible EP platform. The 510(k) clearance allows Imricor to begin commercially marketing the catheter in the United States, the world’s largest electrophysiology market, marking a significant milestone in its US market entry and setting the stage for additional regulatory clearances as the company rolls out its full MRI-guided EP portfolio, with potentially meaningful implications for its growth trajectory and competitive positioning in advanced cardiac ablation technologies.
The most recent analyst rating on (AU:IMR) stock is a Buy with a A$2.22 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.
Imricor Medical Systems has announced that Charité University Hospital in Berlin, one of the world’s leading hospitals, will become the second site globally to join the company’s VISABL-VT clinical trial, which is aimed at advancing real-time MRI-guided ablation for ventricular tachycardia. Following software upgrades to Charité’s Philips MRI system to integrate Imricor’s NorthStar mapping platform and the removal of now-commercial CE-marked Imricor devices from the investigational study framework, the trial protocol has been simplified, and Charité’s electrophysiology team plans to begin commercial atrial flutter ablations in the MRI lab from the first quarter of 2026, underscoring Imricor’s strengthening clinical footprint and its strategic collaboration with Philips in MRI-guided electrophysiology.
The most recent analyst rating on (AU:IMR) stock is a Buy with a A$2.22 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.
Imricor Medical Systems has announced that the University of Virginia Health Medical Center will become the second US site for its VISABL-AFL clinical trial, following IRB approval. This development marks a significant step in Imricor’s efforts to enhance MRI-guided electrophysiology ablations, with procedures expected to begin in February. The expansion to UVA Health is part of a broader strategy to ensure timely enrolment and FDA processes, positioning Imricor to strengthen its market presence and impact in the field of interventional cardiology.
The most recent analyst rating on (AU:IMR) stock is a Buy with a A$2.22 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.